The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Processes for producing oligo-chromopeptides from phycocyanin are disclosed. Additionally, compositions comprising oligo-chromopeptides and combination of oligo-chromopeptides with at least one of the compounds namely, nicotinamide riboside, zinc, selenium, or a combination thereof are disclosed. Uses and methods of treating, preventing, or ameliorating age-related somatic disease, bacterial and/or viral infections/diseases, and diseases associated with oxidative stress, or symptoms associated with any of the foregoing are also disclosed.

Processes for producing oligo-chromopeptides from phycocyanin are disclosed. Additionally, compositions comprising oligo-chromopeptides and combination of oligo-chromopeptides with at least one of the compounds namely, nicotinamide riboside, zinc, selenium, or a combination thereof are disclosed. Uses and methods of treating, preventing, or ameliorating age-related somatic disease, bacterial and/or viral infections/diseases, and diseases associated with oxidative stress, or symptoms associated with any of the foregoing are also disclosed.

Provided herein are Diaminopyrimidine Compounds having the following structures:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

##STR00001##

In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

##STR00001##

The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide.

The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide.

This invention is directed to the use of a combination of antioxidants which are delivered to the gut microbiome. The antioxidants are riboflavin, beta-carotene, Vitamin C and Vitamin E. We have found that they deliver a degree of improvement to gut health comparable to known prebiotics, such as soluble fibers.